Event JSON
{
"id": "d67ab77b93fb67ac4d5ab35a8b4c6f4a4102b16d9dc1080084e7c1c3a6e0ba69",
"pubkey": "6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"created_at": 1731594830,
"kind": 1,
"tags": [
[
"r",
"https://finance.yahoo.com/news/2-beaten-down-dividend-stocks-130000355.html"
],
[
"subject",
"2 Beaten-Down Dividend Stocks to Buy and Hold"
],
[
"published_at",
"1731589200"
],
[
"image",
"https://media.zenfs.com/en/motleyfool.com/5bb82ce761f5a51d32f892f7254f8e8b"
],
[
"p",
"6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"wss://relay-testnet.k8s.layer3.news"
],
[
"imeta",
"url https://media.zenfs.com/en/motleyfool.com/5bb82ce761f5a51d32f892f7254f8e8b"
],
[
"t",
"mainstream:perspective"
],
[
"summary",
"CVS Health has faced revenue growth and net income issues, but is working to resolve its Medicare Advantage business problem. The company has a diversified service offering and a strong position in the healthcare industry. Bristol Myers Squibb has recovered from declining sales following the loss of exclusivity for Revlimid, and is expected to overcome patent cliffs for its best-selling medicines. Both companies have strong dividend yields and have raised their payouts in the past 10 years."
]
],
"content": "nostr:nprofile1qy3hwumn8ghj7un9d3shjtt5v4ehgmn9wshxkwrn9ekxz7t9wgejumn9waesqgr8g2hyzql5lt4cxfjdj40hgtu6vydvsqvsesqy8canygcce3lwvyyapkyy\nhttps://media.zenfs.com/en/motleyfool.com/5bb82ce761f5a51d32f892f7254f8e8b\n\nhttps://finance.yahoo.com/news/2-beaten-down-dividend-stocks-130000355.html",
"sig": "a6f9eef1e1a3b92d01f9db1b9949782e7fad9b401b6887727a74a786bf779a79c5abcc8eb9e51e299d3d1cf4b662655af79b5b95adc5b5c18d85884c4e8b7b83"
}